PCVX - CIK 0001649094
The table below shows Vaxcyte, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $794.31M | $476.64M | $332.34M | $169.45M | $78.41M | $73.56M |
| SG&A | $129.37M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $92.90M |
| $60.70M |
| $39.81M |
| $25.26M |
| $16.02M |
| Operating income | -$923.67M | -$569.55M | -$468.04M | -$232.26M | -$103.67M | -$89.58M |
| Income tax | $0.00 | $0.00 | $0.00 | - | - | - |
| Net income | -$766.63K | -$463.93K | -$402.27K | -$223.49K | -$100.08K | -$89.22M |
| EPS (diluted) | -$5.63 | -$3.80 | -$4.14 | -$3.44 | -$1.93 | -$3.02 |